Bio-rad Laboratories, Inc. (BIO) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Bio-rad Laboratories’s revenue went from $2.1B in fiscal 2016 to $2.6B in fiscal 2025, growth of about 2.5% a year.
Net income in fiscal 2025 was $760M, a net margin of 29.4%; the best year in this period was 2021 with $4.3B.
Over the twelve months to September 30, 2026, revenue was $2.6B and net income $1.0B.
Free cash flow was $375M in fiscal 2025 and positive in 9 of the 10 years shown.
The diluted share count fell 8% over the period (buybacks).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.6B | $2.6B | $2.6B | $2.7B | $2.8B | $2.9B | $2.5B | $2.3B | $2.3B | $2.2B | $2.1B |
| Gross profit | $1.3B | $1.3B | $1.4B | $1.4B | $1.6B | $1.6B | $1.4B | $1.3B | $1.2B | $1.2B | $1.1B |
| Operating income | -$62M | $47M | $269M | $338M | $483M | $500M | $421M | $230M | -$103M | $119M | $56M |
| Net income | $1.0B | $760M | -$1.8B | -$637M | -$3.6B | $4.3B | $3.8B | $1.8B | $366M | $122M | $26M |
| EPS (diluted) | $37.71 | $27.85 | $-65.36 | $-21.82 | $-121.79 | $140.83 | $126.47 | $58.27 | $12.10 | $4.07 | $0.88 |
| R&D | $266M | $276M | $296M | $247M | $257M | $261M | $218M | $203M | $199M | $250M | $206M |
| Revenue growth | — | +0.7% | −3.9% | −4.7% | −4.1% | +14.8% | +10.1% | +1.0% | +6.0% | +4.5% | +2.4% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $468M | $532M | $455M | $375M | $194M | $669M | $585M | $458M | $285M | $104M | $216M |
| Capital spending | -$139M | -$158M | -$166M | -$157M | -$113M | -$134M | -$109M | -$99M | -$130M | -$111M | -$141M |
| Free cash flow | $329M | $375M | $290M | $218M | $82M | $536M | $476M | $359M | $156M | -$7M | $75M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | $79M | $296M | $204M | $429M | $216M | $50M | $100M | $28M | $49M | $3M | $0 |
| Stock-based pay | $61M | $58M | $62M | $61M | $61M | $51M | $42M | $36M | $28M | $23M | $20M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $1.5B | $1.7B | $1.6B | $1.8B | $870M | $991M | $1.1B | $845M | $755M | $839M |
| Debt | — | $1.4B | $1.4B | $1.4B | $1.4B | $223M | $224M | $225M | $439M | $435M | $434M |
| Equity | — | $7.5B | $6.6B | $8.7B | $9.6B | $13.7B | $9.9B | $5.8B | $4.0B | $2.9B | $2.6B |
| Total assets | — | $10.6B | $9.4B | $12.3B | $13.5B | $17.8B | $13.0B | $8.0B | $5.6B | $4.3B | $3.9B |
| Shares (diluted) | 27M | 27M | 28M | 29M | 30M | 30M | 30M | 30M | 30M | 30M | 30M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 51.3% | 51.9% | 53.7% | 53.4% | 55.9% | 56.0% | 56.5% | 54.4% | 53.4% | 55.0% | 55.0% |
| Operating margin | -2.4% | 1.8% | 10.5% | 12.7% | 17.2% | 17.1% | 16.6% | 9.9% | -4.5% | 5.5% | 2.7% |
| Net margin | 39.5% | 29.4% | -71.9% | -23.9% | -129.4% | 145.6% | 149.8% | 76.1% | 16.0% | 5.7% | 1.3% |
| FCF margin | 12.7% | 14.5% | 11.3% | 8.2% | 2.9% | 18.3% | 18.7% | 15.6% | 6.8% | -0.3% | 3.6% |
| ROIC | — | 0.4% | 2.7% | 2.5% | 3.4% | 2.8% | 3.2% | 3.0% | -1.7% | 2.8% | 1.2% |
| ROE | — | 10.2% | -28.1% | -7.3% | -37.7% | 31.1% | 38.6% | 30.6% | 9.1% | 4.2% | 1.0% |
Frequently asked questions
What is Bio-rad Laboratories’s annual revenue?
$2.6B in fiscal 2025 and $2.6B over the twelve months to September 30, 2026.
How much profit does Bio-rad Laboratories make?
Net income was $760M in fiscal 2025 (net margin 29.4%).
Is Bio-rad Laboratories’s revenue growing?
Yes: revenue rose 0.7% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.